Retraction
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: ALTERNATIVE
Paper Information
Record ID:
24119
Author(s):
Journal:
Publication Date:
December 15, 2017
Retraction Date:
August 21, 2020
(5.3 years years ago)
Subjects:
Broad Categories:
Medicine
Medicine
Institutions:
- The Royal Marsden NHS Foundation Trust, London
- Novartis Pharmaceuticals UK Limited, Frimley, United Kingdom
- Centro de Referência da Saúde da Mulher
- Hospital Israelita Albert Einstein, São Paulo, Brazil
- Seoul National University College of Medicine, Seoul
- National Cancer Center, Gyeonggi-do, Korea
- Regional Oncology Dispensary, Arkhangelsk
- N.N. Blokhin Russian Cancer Research Center, Moscow, Russia
- Galina Kurteva, University Cancer Center Hospital, Sofia, Bulgaria
- University of Southern California, Los Angeles, CA
- Aichi Cancer Center Hospital, Aichi, Japan
- Novartis Pharma AG, Basel, Switzerland
- Northwestern University, Chicago, IL
Countries:
Article Type:
Publisher:
American Society of Clinical Oncology
Open Access:
No
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1200/JCO.20.02029Additional Notes:
see also: https://ascopubs.org/doi/abs/10.1200/JCO.20.01894;
Citations (157)
157
Total Citations109
Post-Retraction(69.4%)
47
Pre-Retraction1
Same DayPost-Retraction Citation Analysis
0
Within 30 days
28
Within 1 year
60
After 2+ years
1678
Days since retraction (latest)
UK recommendations for HER2 assessment in breast cancer: an update
Emad A. Rakha, Puay Hoon Tan, Cecily Quinn et al. (11 authors)
Journal of Clinical Pathology
Open Access
Published: Dec 2022
42 citations
42 citations
854 days after retraction
Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review
Ran Ran, Yingying Ma, Hui Wang et al. (5 authors)
Frontiers in Oncology
Open Access
Published: Dec 2022
9 citations
9 citations
854 days after retraction
Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer
Christoph Suppan, Marija Balić
Breast Care
Open Access
Published: Dec 2022
11 citations
11 citations
851 days after retraction
Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
Ye Yuan, Xumei Liu, Yi Cai et al. (4 authors)
Systematic Reviews
Open Access
Published: Dec 2022
27 citations
27 citations
841 days after retraction
Pan-HER Tyrosine Kinase Inhibitor Pyrotinib Enhances Radiosensitivity via ERK1/2 Pathway in HER2-Positive Gastric Cancer
Qian Niu, Jiamin Liu, Ting‐Ting Huang et al. (6 authors)
Oncology Research and Treatment
Open Access
Published: Dec 2022
3 citations
3 citations
839 days after retraction
Real-World Outcome and Prognostic Factors Among HER2-Positive Metastatic Breast Cancer Patients Receiving Pyrotinib-Based Therapy: A Multicenter Retrospective Analysis
Jing Liu, Xianglu Sun, Qianyu Du et al. (12 authors)
Breast Cancer Targets and Therapy
Open Access
Published: Dec 2022
6 citations
6 citations
832 days after retraction
The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review
Shafighe Asgari-Karchekani, Armin Aryannejad, Seied Asadollah Mousavi et al. (5 authors)
Medical Oncology
Published: Sep 2022
13 citations
13 citations
769 days after retraction
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
Gabriel Rinnerthaler, Christian F. Singer, Edgar Petru et al. (18 authors)
Wiener klinische Wochenschrift
Open Access
Published: Sep 2022
2 citations
2 citations
763 days after retraction
Ki-67 Index Provides Long-Term Survival Information for Early-Stage HER2-Low-Positive Breast Cancer: A Single-Institute Retrospective Analysis
Wei‐Xiang Qi, Lingyan Chen, Lu Cao et al. (6 authors)
Journal of Oncology
Open Access
Published: Sep 2022
6 citations
6 citations
753 days after retraction
Breast cancer: an up‐to‐date review and future perspectives
Ruoxi Hong, Binghe Xu
Cancer Communications
Open Access
Published: Sep 2022
222 citations
222 citations
748 days after retraction
Efficacy and safety of pyrotinib‐containing regimen in the patients with HER2‐positive metastatic breast cancer: A multicenter real‐world study
Sha Yin, Yajing Chi, Yangyang Du et al. (10 authors)
Cancer Medicine
Open Access
Published: Jul 2022
15 citations
15 citations
705 days after retraction
Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer
Gábor Rubovszky, Judit Kocsis, Katalin Boér et al. (14 authors)
Pathology & Oncology Research
Open Access
Published: Jul 2022
19 citations
19 citations
689 days after retraction
Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression: features of HER2-low breast cancer
Mengdi Chen, Weilin Chen, Deyue Liu et al. (7 authors)
Breast Cancer
Open Access
Published: Jun 2022
44 citations
44 citations
669 days after retraction
Comparison of adverse effects of trastuzumab with other drug combinations for the treatment of breast cancer: A review
Deepak Kumar, Somnath Basu, Ramesh K. Goyal et al. (5 authors)
Indian Journal of Physiology and Pharmacology
Open Access
Published: May 2022
2 citations
2 citations
648 days after retraction
Onkoloji
Mahmut Büyükşimşek, Mert Tohumcuoğlu, Ali Murat Sedef et al. (28 authors)
Unknown Journal
Open Access
Published: May 2022
636 days after retraction
Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
Julie M. Lebert, Evan J. Lilly
Current Oncology
Open Access
Published: Apr 2022
20 citations
20 citations
595 days after retraction
The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005)
Fangfang Duan, Muyi Zhong, Yuyu Ma et al. (15 authors)
BMC Cancer
Open Access
Published: Mar 2022
1 citation
1 citation
571 days after retraction
Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study
Jian Zhang, Yanchun Meng, Biyun Wang et al. (9 authors)
Frontiers in Oncology
Open Access
Published: Mar 2022
19 citations
19 citations
563 days after retraction
Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival
Federica Miglietta, Michele Bottosso, Gaia Griguolo et al. (5 authors)
ESMO Open
Open Access
Published: Feb 2022
71 citations
71 citations
553 days after retraction
Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review
Yajing Chi, Shang Mao, Liang Xu et al. (10 authors)
Frontiers in Oncology
Open Access
Published: Feb 2022
9 citations
9 citations
544 days after retraction
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
Carrie Wynn, Shou‐Ching Tang
Cancer and Metastasis Reviews
Open Access
Published: Feb 2022
52 citations
52 citations
538 days after retraction
Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
Rupert Bartsch, Simon Peter Gampenrieder, Gabriel Rinnerthaler et al. (10 authors)
Wiener klinische Wochenschrift
Open Access
Published: Jan 2022
2 citations
2 citations
498 days after retraction
Mexican consensus on breast cancer diagnosis and treatment
Jesús Cárdenas-Sánchez
Gaceta Mexicana de Oncología
Open Access
Published: Nov 2021
4 citations
4 citations
460 days after retraction
Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)
Xin Hua, Xiwen Bi, Jianli Zhao et al. (22 authors)
Clinical Cancer Research
Open Access
Published: Nov 2021
50 citations
50 citations
458 days after retraction
A Novel Prognostic Nomogram for the 2-year Survival in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Patients
Mengdi Chen, Jiayi Wu, Deyue Liu et al. (7 authors)
Research Square (Research Square)
Open Access
Published: Nov 2021
438 days after retraction
Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2
Elena Shagisultanova, Lyndsey S. Crump, Michelle Borakove et al. (9 authors)
Molecular Cancer Therapeutics
Open Access
Published: Nov 2021
10 citations
10 citations
438 days after retraction
Effectiveness and safety of pyrotinib‐based therapy in patients with HER2‐positive metastatic breast cancer: A real‐world retrospective study
Chao Li, Xiaoli Bian, Zhaoyun Liu et al. (8 authors)
Cancer Medicine
Open Access
Published: Oct 2021
26 citations
26 citations
426 days after retraction
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Alessandra Gennari, Fabrice André, Carlos H. Barrios et al. (28 authors)
Annals of Oncology
Open Access
Published: Oct 2021
949 citations
949 citations
425 days after retraction
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)
Rosalba Torrisi, Raffaella Palumbo, Rita De Sanctis et al. (15 authors)
Breast Cancer Research and Treatment
Published: Aug 2021
3 citations
3 citations
371 days after retraction
Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer
Susan Dent, Amber Morse, Sarah Burnette et al. (5 authors)
Current Oncology Reports
Open Access
Published: Aug 2021
38 citations
38 citations
371 days after retraction
Clinicopathologic features and treatment advances in cancers with HER2 alterations
Shuyi Cen, Zhen Liu, Hongming Pan et al. (4 authors)
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Published: Aug 2021
17 citations
17 citations
348 days after retraction
Clinical Significance and Genetic Characteristics in HER2 Low Expression Tumors of Hormone Receptor Positive Breast Cancer Patients
Mengdi Chen, Deyue Liu, Weilin Chen et al. (7 authors)
Research Square (Research Square)
Open Access
Published: Aug 2021
348 days after retraction
Complete response to pyrotinib combined with letrozole as first- line treatment of HER2-positive/HR-positive breast cancer: a case report
Ning Xie, Liping Liu, Can Tian et al. (5 authors)
Annals of Translational Medicine
Open Access
Published: Aug 2021
2 citations
2 citations
345 days after retraction
Comparing the reporting and conduct quality of exercise and pharmacological randomised controlled trials: a systematic review
Scott C. Adams, Julia McMillan, Kirsten Salline et al. (10 authors)
BMJ Open
Open Access
Published: Aug 2021
20 citations
20 citations
345 days after retraction
Suggested Modifications to the Management of Patients With Breast Cancer During the COVID-19 Pandemic: Web-Based Survey Study
Shereef Elsamany, Mohamed Elbaiomy, Ahmed A. Zeeneldin et al. (9 authors)
JMIR Cancer
Open Access
Published: Jul 2021
3 citations
3 citations
332 days after retraction
The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer
Fanny Le Du, Véronique Dièras, Giuseppe Curigliano
European Journal of Cancer
Open Access
Published: Jul 2021
41 citations
41 citations
329 days after retraction
Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma
Hamid Maadi, Mohammad Hasan Soheilifar, Wonshik Choi et al. (5 authors)
Cancers
Open Access
Published: Jul 2021
132 citations
132 citations
328 days after retraction
Clinical Consequences of Altering the Definition of HER2-Positive Breast Cancer to Exclude Group 2, HER2-Negative Disease
Steven Sorscher
Journal of the National Comprehensive Cancer Network
Open Access
Published: Jun 2021
2 citations
2 citations
284 days after retraction
Author’s Reply: To the Letter to the Editor by Sorscher
Kimberly H. Allison
Journal of the National Comprehensive Cancer Network
Open Access
Published: Jun 2021
284 days after retraction
Breast cancer
Lyudmila Zhukova, Iuliia I. Andreeva, Л Э Завалишина et al. (23 authors)
Journal of Modern Oncology
Open Access
Published: May 2021
7 citations
7 citations
271 days after retraction
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with <i>PIK3CA</i>-Mutated HER2-Positive Metastatic Breast Cancer
Komal Jhaveri, Joshua Z. Drago, Payal D. Shah et al. (13 authors)
Clinical Cancer Research
Open Access
Published: May 2021
27 citations
27 citations
256 days after retraction
Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib
Lara Ulrich, Alicia Okines
Breast Cancer Targets and Therapy
Open Access
Published: May 2021
17 citations
17 citations
253 days after retraction
Small Molecules in the Treatment of Squamous Cell Carcinomas: Focus on Indirubins
Mirijam Schäfer, Marie Semmler, Thoralf Bernhardt et al. (12 authors)
Cancers
Open Access
Published: Apr 2021
19 citations
19 citations
229 days after retraction
Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases
Emad A. Rakha, Islam M. Miligy, Cecily Quinn et al. (20 authors)
British Journal of Cancer
Open Access
Published: Mar 2021
16 citations
16 citations
215 days after retraction
Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis
Shira Peleg Hasson, M Brezis, Eliya Shachar et al. (6 authors)
ESMO Open
Open Access
Published: Mar 2021
14 citations
14 citations
209 days after retraction
Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
E Cheong, Gwo Fuang Ho
Clinical Case Reports
Open Access
Published: Mar 2021
1 citation
1 citation
196 days after retraction
The changing treatment of metastatic her2‑positive breast cancer (Review)
Maria Mitsogianni, Ioannis P. Trontzas, Georgia Gomatou et al. (6 authors)
Oncology Letters
Open Access
Published: Feb 2021
8 citations
8 citations
175 days after retraction
Clinical data mining reveals analgesic effects of lapatinib in cancer patients
Shuo Zhou, Fang Zheng, Chang‐Guo Zhan
Scientific Reports
Open Access
Published: Feb 2021
3 citations
3 citations
174 days after retraction
Cardiotoxicity in HER2-positive breast cancer patients
Diana Gonciar, Lucian Mocan, Alexandru Zlibut et al. (5 authors)
Heart Failure Reviews
Published: Jan 2021
18 citations
18 citations
138 days after retraction
Quick Stats
Total Citations:
157
Years Since Retraction:
5.3 years
Open Access:
No
Last Checked:
Jul 24, 2025